| Net Profit Growth YoY | 32.58%Quarterly |
|---|---|
| Market Cap | ₹20,661 CrPharmaceuticals |
| Operating Margin | 23.94%Quarterly |
| RSI | 69.12Neutral Zone |
Key highlights
- Granules India secured Sole First-to-File status for Sodium Oxybate Extended-Release for Oral Suspension
- The product is the generic equivalent of LUMRYZ, used to treat cataplexy or excessive daytime sleepiness
- This represents the company's second Sole First-to-File achievement in the complex generics segment
- Quarterly net profit surged 32.58% year-on-year to reach 201.57 crore in the latest report
- Operating revenue for the trailing twelve months stands at 5365.64 crore with a 23.94% quarterly margin
The Product — What It Is
Sodium Oxybate Extended-Release for Oral Suspension is the generic therapeutic equivalent of LUMRYZ, developed by Alkermes. It is specifically indicated for the treatment of cataplexy or excessive daytime sleepiness in adult patients diagnosed with narcolepsy. As a complex generic, the once-nightly extended-release formulation requires advanced manufacturing capabilities to ensure precise controlled drug delivery.
This approval follows Granules success with Amphetamine Extended-Release tablets, marking its second venture into the high-barrier complex generics segment with sole first-to-file status, which often signifies higher barriers to entry for competitors.
Commercial Opportunity
Achieving Sole First-to-File status typically provides a 180-day period of generic marketing exclusivity in the United States, offering a significant competitive advantage. The addressable market for narcolepsy treatments is substantial, with branded once-nightly sodium oxybate formulations addressing critical patient needs for improved dosing regimens. By offering a generic alternative, Granules aims to capture market share in a segment characterized by limited competition and high technical complexity.
This filing strengthens the company’s pipeline in regulated markets where specialized dosage forms command premium positioning compared to standard multi-source generics.
Strategic Fit
This achievement aligns with Granules India’s strategic shift toward a differentiated and complex generics portfolio to drive sustainable long-term growth. The company is leveraging its vertical integration to move beyond high-volume commodity products into value-added specialized formulations. This ANDA status reinforces the company’s R&D strength and its ability to navigate rigorous US FDA regulatory pathways.
By securing its second sole first-to-file status, Granules demonstrates its growing expertise in developing niche products that cater to unmet medical needs while optimizing its manufacturing value chain from APIs to finished dosages.
Business Overview
- Headquartered in Hyderabad, operating across APIs, PFIs, and Finished Dosages
- Maintains 10 global manufacturing facilities across India, the US, and Switzerland
- Distributes products to over 300 customers in more than 80 international markets
- Holds regulatory approvals from major agencies including US FDA, EDQM, and WHO GMP
- Recent expansion into Peptides CDMO services to diversify revenue streams
Financial Context
Granules India reported a 22.81% year-on-year growth in quarterly revenue, reaching 1470.61 crore. Net profit for the same period increased by 34.19% sequentially, reflecting strong operational performance and a shift toward higher-margin products. The company’s annual operating revenue stands at 5365.64 crore, supported by a healthy cash flow from operations of 793.25 crore.
With a stock return of 69.27% over the past year, the company maintains a Piotroski Score of 7, indicating robust financial health as it continues to reinvest in its complex generics pipeline.
“Securing Sole First-to-File status for our Sodium Oxybate Extended Release for Oral Suspension ANDA is another important milestone in our complex generics journey.”
| Share price | ₹833.8 |
|---|---|
| Market capitalisation | ₹20,661.31 Cr |
| Revenue (annual) | ₹5,365.64 Cr |
| Net profit (annual) | ₹595.02 Cr |
| Revenue (latest quarter) | ₹1,470.61 Cr+5.96% vs previous quarter |
| Net profit (latest quarter) | ₹201.57 Cr+34.19% vs previous quarter |
| P/E (TTM) | 34.72×Sector 42.57× |
| Promoter holding | 38.02%0.00% QoQ |
| FII holding | 17.5%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Granules India Limited announcing the receipt of Sole First-to-File ANDA status for Sodium Oxybate Extended-Release. Market figures from a third-party data provider.
